- Motley Fool•3 hours ago
Gilead Sciences might want to pay attention to Allergan's aggressive expansion of its NASH program.
- The Wall Street Journal•yesterday
Subjects at high risk of developing Alzheimer’s—but who don’t actually have the disease—are being recruited to help test two experimental treatments from Novartis AG, in a new focus on preventive treatment....
- Market Realist•2 days ago
Novartis’s (NVS) Innovative Medicines segment includes products for therapeutic areas such as oncology, cardiometabolic, immunology, and dermatology.
NVS : Summary for Novartis AG - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||73.31 - 73.83|
|52 Week Range||66.93 - 83.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||26.21|
|Dividend & Yield||2.72 (3.71%)|
|1y Target Est||N/A|